Tenaya Therapeutics, Inc. (TNYA) Income Statement
TNYA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTNYA revenue and net income
TNYA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TNYA quarterly EPS vs estimates
Tenaya Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.10).
TNYA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $8.4M | $8.5M | $8.7M | $8.7M | $4.0M | $2.5M | $2.0M |
| Gross profit | −$8.4M | −$8.5M | −$8.7M | −$8.7M | −$4.0M | −$2.5M | −$2.0M |
| Research & development | $68.6M | $86.7M | $98.0M | $94.5M | $54.4M | $31.1M | $23.1M |
| Sales, general & admin | $24.7M | $29.2M | $33.2M | $31.1M | $18.4M | $7.8M | $4.6M |
| Total operating expenses | $84.9M | $107.5M | $122.5M | $125.6M | $72.8M | $36.4M | $27.7M |
| Operating income | −$93.3M | −$115.9M | −$131.2M | −$125.6M | −$72.8M | −$38.9M | −$27.7M |
| Interest income | $2.7M | $4.7M | $6.6M | $2.0M | $108,000 | $87,000 | $453,000 |
| Interest expense | — | — | — | $1,956 | $72.7M | $0 | $0 |
| Income before taxes | −$90.6M | −$111.1M | −$124.1M | −$123.7M | −$72.7M | −$38.4M | −$26.2M |
| Income taxes | — | −$111.1M | $8.5M | −$1,956 | −$3.1M | −$87,000 | −$453,000 |
| Net income | −$90.6M | −$111.1M | −$124.1M | −$123.7M | −$69.7M | −$38.4M | −$25.8M |
| EBITDA | −$82.2M | −$102.7M | −$115.4M | −$119.2M | −$69.8M | −$35.9M | −$25.7M |
| EPS (diluted) | −$0.62 | −$1.32 | −$1.67 | −$2.79 | −$14.97 | −$11.93 | −$10.15 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $225,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $17.7M | $0 |
| Cost of revenue | $0 | $1.8M | −$3.9M | $1.9M | $2.1M | — | — | — | $2.1M | $2.2M | $3.0M | $3.0M |
| Gross profit | $1.1M | −$1.5M | $3.9M | −$1.9M | −$2.1M | — | — | — | −$2.1M | −$2.2M | −$3.0M | −$3.0M |
| Research & development | $16.6M | $14.8M | $14.8M | $15.4M | $17.4M | $21.1M | $18.7M | $20.4M | $22.6M | $25.1M | $22.9M | $23.1M |
| Sales, general & admin | $5.4M | $5.4M | $6.0M | $5.6M | $6.7M | $6.5M | $6.0M | $6.4M | $8.2M | $8.7M | $8.6M | $7.8M |
| Total operating expenses | $45.2M | $18.5M | $24.7M | $20.9M | $22.0M | $27.5M | $24.7M | $26.7M | $28.7M | $31.6M | $28.5M | $27.9M |
| Operating income | −$44.1M | −$20.1M | −$20.8M | −$20.9M | −$24.1M | −$27.5M | −$24.7M | −$26.7M | −$30.8M | −$33.8M | −$31.4M | −$30.9M |
| Interest income | $697,000 | $793,000 | $575,000 | $658,000 | $815,000 | $635,000 | $812,000 | $1.1M | $1.4M | $1.5M | $1.5M | $1.8M |
| Income before taxes | −$43.4M | −$19.3M | −$20.2M | −$20.3M | −$23.3M | −$26.9M | −$23.8M | −$25.6M | −$29.4M | −$32.2M | −$29.9M | −$29.1M |
| Income taxes | — | — | — | — | — | — | — | — | — | $2.1M | $2.9M | $3.0M |
| Net income | −$43.4M | −$19.3M | −$20.2M | −$20.3M | −$23.3M | −$26.9M | −$23.8M | −$25.6M | −$29.4M | −$32.2M | −$29.9M | −$29.1M |
| EBITDA | −$41.7M | −$17.5M | −$18.3M | −$18.4M | −$21.2M | −$24.2M | −$21.7M | −$23.5M | −$27.3M | −$30.1M | −$26.9M | −$26.2M |
| EPS (diluted) | −$0.09 | −$0.09 | −$0.12 | −$0.12 | −$0.14 | −$0.24 | −$0.28 | −$0.30 | −$0.34 | −$0.40 | −$0.40 | −$0.39 |
| Gross margin | 100.0% | −683.6% | — | — | — | — | — | — | — | — | −16.9% | — |
| Operating margin | −3,971.9% | −8,917.8% | — | — | — | — | — | — | — | — | −178.0% | — |
| Net margin | −3,909.3% | −8,565.3% | — | — | — | — | — | — | — | — | −169.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TNYA's financial statements (latest annual report filed March 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TNYA financial results
Tenaya Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $90.6 million. Diluted earnings per share came to −$0.62.
See the TNYA stock overview for the latest quote and news, or the TNYA chart for price history and technical indicators.
TNYA income statement FAQ
Does Tenaya Therapeutics have revenue?
Tenaya Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Tenaya Therapeutics profitable?
No. Tenaya Therapeutics reported a net loss of $90.6 million in fiscal 2025.
How much does Tenaya Therapeutics spend on research and development?
Tenaya Therapeutics spent $68.6 million on research and development in fiscal 2025.
What are Tenaya Therapeutics's earnings per share?
Tenaya Therapeutics earned $-0.62 per diluted share in fiscal 2025, compared with $-1.32 a year earlier.
When will Tenaya Therapeutics report its next earnings?
Tenaya Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Tenaya Therapeutics's fiscal year end?
Tenaya Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 11, 2026.